Over the past few years, with the advent of many new drugs for AML, including venetoclax combinations and a molecularly defined class of targeted therapies, IDH1/2 or FLT3 inhibitors, it is uncertain if this classification would still apply [59]. This evidence concerns the gene IDH1 and acute myeloid leukemia.